These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7988099)

  • 21. Adverse drug reaction monitoring in a secondary care hospital in South India.
    Arulmani R; Rajendran SD; Suresh B
    Br J Clin Pharmacol; 2008 Feb; 65(2):210-6. PubMed ID: 17662089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug dosing in elderly patients with chronic kidney disease.
    Lassiter J; Bennett WM; Olyaei AJ
    Clin Geriatr Med; 2013 Aug; 29(3):657-705. PubMed ID: 23849014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Practical value of active prospective monitoring of drug therapy safety].
    Ovchinnikova EA; Nazimkin KE; Iagudina RI
    Antibiot Khimioter; 2006; 51(9-10):40-6. PubMed ID: 18030790
    [No Abstract]   [Full Text] [Related]  

  • 24. Intentional rechallenge and the clinical management of drug-related problems.
    Meyboom R
    Drug Saf; 2013 Mar; 36(3):163-5. PubMed ID: 23475582
    [No Abstract]   [Full Text] [Related]  

  • 25. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.
    Jannetto PJ; Bratanow NC
    Pharmacogenomics; 2009 Jul; 10(7):1157-67. PubMed ID: 19604091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?
    Senior JR
    Clin Pharmacol Ther; 2009 Mar; 85(3):331-4. PubMed ID: 19129750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Information on adverse events in randomised clinical trials assessing drug interventions published in four medical journals with high impact factors.
    Maggi CB; Griebeler IH; Dal Pizzol Tda S
    Int J Risk Saf Med; 2014; 26(1):9-22. PubMed ID: 24796347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring--the appropriate use of drug level measurement in the care of the neonate.
    Young TE
    Clin Perinatol; 2012 Mar; 39(1):25-31. PubMed ID: 22341534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?
    Weismantel D; Danis P
    J Fam Pract; 2001 Nov; 50(11):927-8. PubMed ID: 11711005
    [No Abstract]   [Full Text] [Related]  

  • 31. [Issues in therapeutic drug monitoring evaluation].
    Paintaud G; Le Guellec C; Furet Y; Autret-Leca E
    Therapie; 2001; 56(3):245-9. PubMed ID: 11475802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Technology today: bispectral index monitoring.
    Luebbehusen M
    RN; 2005 Sep; 68(9):50-4; quiz 55. PubMed ID: 16207003
    [No Abstract]   [Full Text] [Related]  

  • 33. The adverse drug reaction: a clinical opportunity for pharmacists.
    Miller JD
    Hosp Pharm; 1995 Sep; 30(9):769-73. PubMed ID: 10151281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry.
    Gerlach M; Egberts K; Dang SY; Plener P; Taurines R; Mehler-Wex C; Romanos M
    Expert Opin Drug Saf; 2016 Nov; 15(11):1477-1482. PubMed ID: 27551945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Polypharmacy - Solutions for Enhanced Drug Safety].
    Krause O; Picksak G; Junius-Walker U
    Dtsch Med Wochenschr; 2017 Jul; 142(14):1046-1053. PubMed ID: 28728199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoting adverse drug reaction reporting: comparison of different approaches.
    Ribeiro-Vaz I; Santos CC; Cruz-Correia R
    Rev Saude Publica; 2016; 50():14. PubMed ID: 27143614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of a computerized drug-monitoring program to detect and prevent adverse drug events and medication non-adherence in outpatient ambulatory care: study protocol of a randomized controlled trial.
    Forster AJ; Erlanger TE; Jennings A; Auger C; Buckeridge D; van Walraven C; Tamblyn R
    Trials; 2015 Jan; 16():2. PubMed ID: 25572800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How important is therapeutic drug monitoring in the prediction and avoidance of adverse reactions?
    Gentry CA; Rodvold KA
    Drug Saf; 1995 Jun; 12(6):359-63. PubMed ID: 8527010
    [No Abstract]   [Full Text] [Related]  

  • 39. Ribavirin therapeutic drug monitoring: why, when and how?
    Stanke-Labesque F; Loustaud-Ratti V; Babany G; Gagnieu MC; Marquet P;
    Fundam Clin Pharmacol; 2010 Aug; 24(4):401-6. PubMed ID: 19788564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine].
    Yan BH; Peng C; Xie YM; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.